← Back to Clinical Trials
Recruiting NCT07640282

NCT07640282 ESP Block vs. EXORA Block for Postoperative Pain in Nephrectomy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07640282
Status Recruiting
Phase
Sponsor Bakirkoy Dr. Sadi Konuk Research and Training Hospital
Condition Postoperative Pain
Study Type OBSERVATIONAL
Enrollment 84 participants
Start Date 2026-06
Primary Completion 2029-08

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type OBSERVATIONAL
Interventions
Erector Spinae Plane BlockExternal Oblique Rectus Abdominis Block

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 84 participants in total. It began in 2026-06 with a primary completion date of 2029-08.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this observational study is to learn about the effects of two pain control techniques used after laparoscopic nephrectomy (kidney removal surgery) in adults. The study will compare Erector Spinae Plane (ESP) block and External Oblique Rectus Abdominis (EXORA) block, which are both used as part of routine medical care to help control pain after surgery. The main questions it aims to answer are: Do ESP block and EXORA block differ in how well they control pain after surgery? Do ESP block and EXORA block differ in their effects on recovery quality and the need for additional pain medication? Researchers will compare participants who receive ESP block with participants who receive EXORA block as part of routine clinical care. Participants will: Undergo laparoscopic nephrectomy according to routine clinical practice. Receive either ESP block or EXORA block based on the treating anesthesiologist's usual clinical preference. Complete a recovery questionnaire before surgery and 24 hours after surgery. Have pain scores, use of additional pain medication, nausea and vomiting, and other routine postoperative measurements recorded during the first 24 hours after surgery.

Eligibility Criteria

Inclusion Criteria: * Age between 18 and 80 years * Patients scheduled for laparoscopic nephrectomy * Patients for whom Erector Spinae Plane (ESP) block or External Oblique Rectus Abdominis (EXORA) block has been selected by the treating clinician * ASA physical status I-III Exclusion Criteria: * No regional block performed in routine clinical practice * Body mass index (BMI) greater than 35 kg/m² * History of opioid dependence * Alcohol or other substance dependence * Psychiatric disease, mental retardation, dementia, or any condition impairing pain perception or pain assessment

Contact & Investigator

Central Contact

Şeyma Nur Güner Zengin, MD

✉ snurguner@gmail.com

📞 +90 212 414 71 71

Frequently Asked Questions

Who can join the NCT07640282 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Postoperative Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07640282 currently recruiting?

Yes, NCT07640282 is actively recruiting participants. Contact the research team at snurguner@gmail.com for enrollment information.

Where is the NCT07640282 trial being conducted?

This trial is being conducted at Istanbul, Turkey (Türkiye).

Who is sponsoring the NCT07640282 clinical trial?

NCT07640282 is sponsored by Bakirkoy Dr. Sadi Konuk Research and Training Hospital. The trial plans to enroll 84 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology